S. Jeson Sangaralingham, Ph.D., M.S., is a translational cardiovascular investigator who studies biological mechanisms and signaling cascades that contribute to adverse cardiorenal fibrosis, remodeling and failure. His primary focus is on the protective role of the natriuretic peptide-particulate guanylyl cyclase-cyclic guanosine monophosphate (NP-pGC-cGMP) system. Using this scientific knowledge, Dr. Sangaralingham and his team are leading efforts to discover, engineer and develop innovative drugs that enhance the protective actions of the pGC-cGMP system for cardiorenal diseases such as heart failure, ischemic heart disease, hypertension and chronic kidney disease.
Dr. Sangaralingham is also committed to identifying novel plasma and urinary natriuretic-based biomarkers for use in diagnosis and prognosis of cardiorenal disease. His investigational techniques include pGC-cGMP-targeted drug discovery (peptide and small molecule based) and engineering, in vitro biomolecular studies in human primary cell lines, in vivo experimental animal models of human cardiorenal disease including organ function and tissue analysis, and human population studies including natriuretic-based biomarker discovery and proof-of-principle clinical trials. He has a number of issued and pending patents worldwide and his research program is funded by the National Institutes of Health.
- Natriuretic peptide and small-molecule-based drug discovery, design and development
- Cardiorenal fibrosis, remodeling and failure
- Cardiorenal protection
- Pathophysiology of cardiorenal diseases such as heart failure, ischemic heart disease, hypertension and chronic kidney disease
- Natriuretic peptide-based plasma and urinary biomarkers to identify and track cardiorenal injury and disease as well as predict clinical outcomes
Significance to patient care
Dr. Sangaralingham's translational cardiovascular research program is of great clinical impact, as the burden of cardiorenal disease worldwide is significant. He is highly focused on transforming scientific ideas and discoveries at the bench into novel therapeutic, diagnostic and prognostic strategies at the bedside, with goals of reducing the burden of cardiorenal disease and improving the quality of life for patients.
- Principal investigator, R01 grants awarded from the National Heart, Lung, and Blood Institute and National Institute on Aging
- Associate director, Discovery, National Institutes of Health Cardiovasology Program
- Fellow, American Heart Association
- Recipient, Scientist Development Grant, American Heart Association
- Recipient, Career Development Award in Cardiovascular Research, St. Jude Medical
- Recipient, Jay N. Cohn New Investigator Award, Clinical/Integrative Physiology, Heart Failure Society of America